Starting with clinical needs.
Advancing natural medicines with AI.
Our three research directions are natural-origin original molecules, global botanical drugs and innovative TCM drugs. We use AI prediction to identify candidates and experimental research to evaluate pharmacological effects and mechanisms, advancing each program according to its product definition and regulatory pathway.
01 Natural-origin original molecules
Start from natural products to investigate active compounds, novel scaffolds and optimization opportunities. Connect molecular discovery with testable development paths through mechanistic analysis, medicinal chemistry and developability assessment. Natural origin alone does not establish eligibility as a new chemical entity.
Explore this direction ↗02 Global botanical drugs
Start with a defined modern medical indication. Use VMED-OS to predict and prioritize botanical candidates, then investigate composition, mechanisms, pharmacology and safety. Align material, process, quality and clinical development with each target market’s botanical drug requirements.
Explore this direction ↗03 Innovative TCM drugs
Focus on China’s Class 1 innovative TCM drugs: Class 1.1 compound preparations; Class 1.2 extracts from a single plant, animal, mineral or other material and their preparations; and Class 1.3 new medicinal materials and their preparations. Connect TCM theory, human-use experience and clinical research around clinical value.
Explore this direction ↗Shared capabilities. Distinct development paths.
The three directions share AI reasoning, constituent analysis, pharmacology and quality research. Product definition and the intended market determine the path. One source material can inform different products, each with its own classification and evidence requirements.
Explore research partnerships
Discuss candidate resources, product goals and next-stage plans across our three research directions.
Partnering ↗